King Hussein Cancer Center
Amman, 11941, Jordan
NCT Number: NCT04759638
There is a controversy regarding the effect of the two Body Mass Index (BMI) extremes on the oncological outcome of rectal cancer.
The obesity paradox appears to exist in rectal cancer patients treated with nCRT and surgery, as it was associated with significantly higher rates of pathological complete response and R0 resection.
Underweight patients were at higher risk for anastomotic leak and R1 resection.
Looking for future studies?
Notify MeObservational
Amman, 11941, Jordan
Background:
Obesity and underweight are associated with increased risk of postoperative morbidity in colorectal cancer patients undergoing surgery. There is a controversy regarding the effect of the two Body Mass Index (BMI) extremes on the oncological outcome of rectal cancer.
Objective:
The aim of this study was to evaluate the effect of BMI on short- and long-term oncological outcomes as well as postoperative complications in rectal cancer patients who received neoadjuvant chemoradiotherapy (nCRT) followed by surgery.
Setting:
Tertiary Cancer Center serving pediatric and adult patients in Jordan and the Middle East.
Patients:
The medical records of patients with stage II-III rectal cancer who received nCRT followed by surgery during 2006 to 2018 were retrospectively reviewed. The patients were subdivided according to their BMI into less than 20 kg/m2 defined as underweight; between 20 to 30 kg/m2 defined as normal range weight, above 30 kg/m2 defined as obese.
Main Outcome Measures:
Disease-Free Survival (DFS), Overall Survival, Pathological Complete Response (CR)
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 5 yers
Disease-free survival (DFS) was defined as the time from surgical resection to disease recurrence (including loco-regional failure or metastases) or death of any cause
Time frame: 5 years
Overall survival (OS) was defined as the time interval from surgical resection to either death from any cause or last follow up
Time frame: 5 years
Pathological CR was defined as no viable cancer cells in the excised specimen.
King Hussein Cancer Center
Other
Body Mass Index Role in the Oncological Outcome of Locally Advanced Rectal Cancer: The Two BMI Extremes as Comparative Groups, A Retrospective Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02632448
Adnexal Diseases, Breast Cancer
Boston, Massachusetts, United States
View Trial DetailsNCT05943041
Cancer, Colonic Diseases
Seoul, Gangnam-gu, South Korea
View Trial DetailsNCT04028479
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Idaho Falls, Idaho, United States
View Trial DetailsNCT00020267
Adult Soft Tissue Sarcoma, Bone Cancer
Bethesda, Maryland, United States
View Trial Details